- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05772676
The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting
The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastric Sleeve Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After being informed about the study, all patients who provide written informed consent and meet the eligibility requirements will be randomized in a triple-blind manner (participant, evaluator, and investigator) in a 1:1 ratio to Aprepitant (80 or 125 mg) + standard antiemetic regimen (once two hours before surgery) or placebo + standard antiemetic regimen(once two hours before surgery).
The standard antiemetic regimen will be Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico
- Hospital General Tlahuac
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 65 years old.
- Non-smokers.
- Obesity with BMI > 30 kg/m2.
- Undergoing laparoscopic gastric sleeve.
Exclusion Criteria:
- Documented hypersensitivity to any component of the study regimen.
- Current treatment with: Orap (pimozide), Seldane (terfenadine), Hismanal (astemizole) or Propulsid (cisapride).
- Allergy to opioid drugs used in the anesthetic protocol.
- Drug or alcohol abuse.
- Chronic nausea and vomiting.
- Previous bariatric procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Aprepitant
Aprepitant (80 or 125 mg) + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
|
80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
|
|
Placebo Comparator: Placebo
Placebo + Ondansetron 8 mg + Metoclopramide 10 mg + Dexamethasone 8 mg
|
Placebo + standard antiemetic regimen, once two hours before surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient's postoperative nausea and vomiting evaluation at 0 hrs (Rhodes index)
Time Frame: 0 postoperative hours
|
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhodes scale
|
0 postoperative hours
|
|
Patient's postoperative nausea and vomiting evaluation at 6 hrs (Rhodes index)
Time Frame: 6 postoperative hours
|
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhoades scale
|
6 postoperative hours
|
|
Patient's postoperative nausea and vomiting evaluation at 12 hrs (Rhodes index)
Time Frame: 12 postoperative hours
|
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhoades scale
|
12 postoperative hours
|
|
Patient's postoperative nausea and vomiting evaluation at 24 hrs (Rhodes index)
Time Frame: 24 postoperative hours
|
Change of postoperative nausea and vomiting after laparoscopic gastric sleeve using Rhoades scale
|
24 postoperative hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Neurokinin-1 Receptor Antagonists
- Aprepitant
Other Study ID Numbers
- APREPITANTBAJAMED-01-2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.